Page 10 of 32 · 749 questions tagged coa.
The case in front of me: Homopeptide · oral semaglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points…
Concretely: Homopeptide · tirzepatide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Is…
Numbers first: sampling plan · WXT. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
Setup, so nobody has to ask: 99.4% · a C18 column · ecnoglutide. I have read the primary source rather than the summary, which has left me with more questions. I…
This is a United States plan; I appreciate the answer is jurisdiction-specific. The empirical answer seems settled. The explanation does not. If the honest answer is…
Setup, so nobody has to ask: QSC · cagrilintide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…
I have kept every message, invoice and document, which I gather is the useful habit. I can find plenty of assertions about this and almost no reasoning, which is…
Concretely: ecnoglutide · twelve weeks · 30 °C. I want to decide this in advance so that I am not deciding it under pressure later. Assume I will follow the plan I…
Concretely: 99.1% · a C4 column · orforglipron. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
The case in front of me: VendorInvestigate · Shanghai Wibson Biotechnology. The figures are clear enough; the question is what they mean and what they do not. I can…
This is my second independent submission on material from the same supplier. I can parse the result. I am less sure what it licenses me to conclude. I have…
What I have: batch certificate · FGP. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Conditions: 98.8% · method section. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
What I am working with: retatrutide · two weeks · 25 °C. I am trying to build something sustainable rather than something thorough that I will abandon. I have already…
The method section is present, which is unusual enough that I want to make use of it. These are treated as interchangeable and I do not think they are. If both are…
Concretely: 97.1% · a C4 column · orforglipron. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…
Details up front: 99.4% · purity figure. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
Details up front: JEEP · Flourishglobal Peptide Biotech. I have used one of these for a while and I am considering switching, which requires a reason. What I care…
This is my second independent submission on material from the same supplier. I have the document in front of me and I can read the numbers. What I cannot do is…
Conditions: survodutide · four weeks · 40 °C. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like…
What I have: JEEP · a quantified content assay. This should be a straightforward calculation and I keep getting two different answers. The numbers are arbitrary; the…
For reference: SSA · Hunan Aslsen Technology. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for each and…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I want to understand what this actually establishes, as opposed to what it…
What I have: mazdutide · sixteen weeks · minus 20 °C. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me…